In Brief: Immucor
This article was originally published in The Gray Sheet
Executive Summary
Immucor: Responds to FDA's questions on a 510(k) submission for its ABS2000 automated analyzer for blood banks, the Norcross, Georgia-based firm says Sept. 22. FDA's questions addressed "the instrument, software, and the company's reagent products used to run" the ABS2000, which Immucor developed to automate "certain labor intensive, time consuming blood transfusion compatibility tests currently performed manually by laboratory technologists." Immucor submitted a 510(k) for the device on March 18, 1996 ("The Gray Sheet" March 25, 1996, In Brief)...
You may also be interested in...
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.